Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies.

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJun LiKLKaichun LiuJFJianmin Fu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e67054b6db6435875fa8cbhttps://doi.org/10.1200/jco.2024.42.16_suppl.e14531
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD7 CAR-T therapy: current developments, improvements, and dilemmas2025 · 5 citations
  2. 2Intracellular retention of TCRαβ/CD3 to generate novel allogeneic CAR-T cells targeting CLL1 for treating acute myelocytic leukemia.2024 · 1 citations
  3. 3CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
  4. 4Abstract LB341: Clinical validation and mechanistic insights of ThisCART: A novel allogeneic platform enhancing CAR-T signaling via intracellular TCRαβ/CD3 retention2024
  5. 5Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation2024 · 4 citations